Skip to the beginning of the images gallery

Opicinumab (anti-LINGO1) - Primary antibody, specific to LINGO1, >95%, high purity, Human IgG1, Antibody of leucine rich repeat and Ig domain containing 1

≥95%(SDS-PAGE&SEC)
Lot by Lot

Features and benefits

Short Overview:
Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated
Species reactivity(Reacts with): Human
Isotype: Human IgG1

Application:

Animal Model
ELISA
Flow Cytometry
Functional Assay

Item Number

Ab175619

Grouped product items
SKU	Size	Availability	Price
Ab175619-100μg	100μg	In stock	$109.90
Ab175619-1mg	1mg	In stock	$519.90
Ab175619-5mg	5mg	In stock	$1,399.90
Ab175619-10mg	10mg	Available within 8-12 weeks(?) Production requires sourcing of materials. We appreciate your patience and understanding.	$2,239.90

Purity>95% (SDS-PAGE&SEC); Endotoxin Level<1.0EU/mg; Human IgG1; CHO; ELISA, FACS, Functional assay, Animal Model; Unconjugated

View related series

Click to view target information: LINGO1

Accession#:Q96FE5 Gene ID:84894 leucine rich repeat and Ig domain containing 1 Antibody LINGO1

Basic Description

Product Name	Opicinumab (anti-LINGO1) - Primary antibody, specific to LINGO1, >95%, high purity, Human IgG1
Synonyms	LJ14594 antibody; LERN 1 antibody; LERN1 antibody; Leucine rich repeat and Ig domain containing 1 antibody; Leucine rich repeat neuronal 6A antibody; Leucine rich repeat neuronal protein 1 antibody; Leucine rich repeat neuronal protein 6A antibody; Leucin
Specifications & Purity	ExactAb™, Validated, Carrier Free, Low Endotoxin, Azide Free, Recombinant, ≥95%(SDS-PAGE&SEC), Lot by Lot
Specificity	LINGO1
Conjugation	Unconjugated
Grade	Azide Free, Carrier Free, ExactAb™, Low Endotoxin, Recombinant, Validated
Action Type	INHIBITOR
Mechanism of action	Antibody of leucine rich repeat and Ig domain containing 1
Product Description	Opicinumab (anti-LINGO1) is a monoclonal antibody against LINGO-1 and has potential application in acute optic neuritis and relapse multiple sclerosis.

Product Properties

Isotype	Human IgG1
Light Chain Type	kappa
SDS-PAGE	27.4 kDa (Light Chain) & 53.9 kDa (Heavy Chain), under reducing conditions; 181.1 kDa, under non-reducing conditions.
Purification Method	Protein A purified
Purity	>95%
Form	Liquid
Concentration	Lot by Lot
Storage Temp	Store at -80°C,Avoid repeated freezing and thawing
Shipped In	Ice chest + Ice pads
Stability And Storage	Store at -80℃ for 24 months. Upon delivery aliquot. Avoid freeze/thaw cycle.
CAS	1422268-07-2

Associated Targets(Human)

LINGO1 Tbio Leucine-rich repeat and immunoglobulin-like domain-containing nogo receptor-interacting protein 1 (0 Activities)

Discover Target: LINGO1

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

LINGO1 Tbio Leucine-rich repeat and immunoglobulin-like domain-containing nogo receptor-interacting protein 1 (0 Activities)

Discover Target: LINGO1

Activity Type	Relation	Activity value	Units	Action Type	Journal	PubMed Id	doi	Assay Aladdin ID

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

Find and download the COA for your product by matching the lot number on the packaging.

3 results found

Lot Number	Certificate Type	Date	Item
ZJ24F0303696	Certificate of Analysis	Mar 26, 2024	Ab175619
ZJ24F0303695	Certificate of Analysis	Mar 26, 2024	Ab175619
ZJ24F0303694	Certificate of Analysis	Mar 26, 2024	Ab175619

References

1. Shams PN, Plant GT. (2009) Optic neuritis: a review.. Int MS J, 16 (3): (82-9). [PMID:19878630]
2. Mi S, Pepinsky RB, Cadavid D. (2013) Blocking LINGO-1 as a therapy to promote CNS repair: from concept to the clinic.. CNS Drugs, 27 (7): (493-503). [PMID:23681979]
3. Pepinsky RB, Arndt JW, Quan C, Gao Y, Quintero-Monzon O, Lee X, Mi S. (2014) Structure of the LINGO-1-anti-LINGO-1 Li81 antibody complex provides insights into the biology of LINGO-1 and the mechanism of action of the antibody therapy.. J Pharmacol Exp Ther, 350 (1): (110-23). [PMID:24756303]
4. Tran JQ, Rana J, Barkhof F, Melamed I, Gevorkyan H, Wattjes MP, de Jong R, Brosofsky K, Ray S, Xu L et al.. (2014) Randomized phase I trials of the safety/tolerability of anti-LINGO-1 monoclonal antibody BIIB033.. Neurol Neuroimmunol Neuroinflamm, 1 (2): (e18). [PMID:25340070]
5. Mi S, Lee X, Shao Z, Thill G, Ji B, Relton J, Levesque M, Allaire N, Perrin S, Sands B et al.. (2004) LINGO-1 is a component of the Nogo-66 receptor/p75 signaling complex.. Nat Neurosci, 7 (3): (221-8). [PMID:14966521]
6. Mosyak L, Wood A, Dwyer B, Buddha M, Johnson M, Aulabaugh A, Zhong X, Presman E, Benard S, Kelleher K et al.. (2006) The structure of the Lingo-1 ectodomain, a module implicated in central nervous system repair inhibition.. J Biol Chem, 281 (47): (36378-90). [PMID:17005555]
7. Carim-Todd, Laura L, Escarceller, Mònica M, Estivill, Xavier X and Sumoy, Lauro L.. (2003) LRRN6A/LERN1 (leucine-rich repeat neuronal protein 1), a novel gene with enriched expression in limbic system and neocortex.. The European journal of neuroscience, [PMID:14686891]
8. Inoue, Haruhisa H and 12 more authors.. (2007) Inhibition of the leucine-rich repeat protein LINGO-1 enhances survival, structure, and function of dopaminergic neurons in Parkinson's disease models.. Proceedings of the National Academy of Sciences of the United States of America, (4): [PMID:17726113]
9. Budel, Stéphane S and 18 more authors.. (2008) Genetic variants of Nogo-66 receptor with possible association to schizophrenia block myelin inhibition of axon growth.. The Journal of neuroscience : the official journal of the Society for Neuroscience, (3): [PMID:19052207]
10. Ansar, Muhammad M and 25 more authors.. (2018) Biallelic variants in LINGO1 are associated with autosomal recessive intellectual disability, microcephaly, speech and motor delay.. Genetics in medicine : official journal of the American College of Medical Genetics, [PMID:28837161]

Solution Calculators

Molarity Calculator

Determine the necessary mass, volume, or concentration for preparing a solution.

Dilution Calculator

Determine the dilution needed to prepare a stock solution.